XORTX (XRTX) wins approvals for 1-for-5 share consolidation effective April 6, 2026

Rhea-AI Filing Summary

XORTX Therapeutics Inc. filed a Form 6-K confirming the effective details of its previously announced share consolidation. The consolidation will occur on April 6, 2026, on the basis of one new common share for every five old common shares, following approvals from the TSX Venture Exchange and Nasdaq Stock Exchange.

The company is a late-stage clinical pharmaceutical business with three clinically advanced programs targeting gout and progressive kidney diseases, plus an additional pre-clinical program for Type 2 diabetic nephropathy.

Key Figures

Share consolidation ratio: 1 new share for every 5 old common shares Consolidation effective date: April 6, 2026 Clinically advanced programs: 3 products in development +1 more

4 metrics

Share consolidation ratio 1 new share for every 5 old common shares Consolidation basis approved by TSX Venture Exchange and Nasdaq

Consolidation effective date April 6, 2026 Implementation date for XORTX share consolidation

Clinically advanced programs 3 products in development XRx-026, XRx-008 and XRx-101

Pre-clinical program XRx-225 Program for Type 2 diabetic nephropathy

Key Terms

share consolidation, TSX Venture Exchange, Nasdaq Stock Exchange, forward-looking statements, +2 more

6 terms

share consolidation financial

"the implementation of its share consolidation on the basis of one (1) new common share for every five (5) old common shares"

Share consolidation is a process where a company reduces the total number of its shares by combining multiple existing shares into a smaller number of higher-value shares. This can make each share more expensive and potentially improve the company’s image. For investors, it often means their ownership remains the same, but the value of each share increases, which can influence how the stock is perceived and traded.

TSX Venture Exchange regulatory

"has received all required approvals of the TSX Venture Exchange and Nasdaq Stock Exchange"

A junior stock exchange in Canada where smaller, early-stage companies list shares to raise capital and gain public visibility. Think of it as a farmers’ market for young businesses: it offers investors a chance to buy into fast-growing but higher-risk ventures, with looser listing rules and typically lower liquidity than major exchanges. It matters because performance and financing on this exchange can signal growth prospects or risk for investors.

Nasdaq Stock Exchange regulatory

"has received all required approvals of the TSX Venture Exchange and Nasdaq Stock Exchange"

A U.S.-based electronic stock exchange where shares of many publicly traded companies are bought and sold, functioning like a large online marketplace for stocks. It matters to investors because it provides a central place for real-time prices and easy trading, enforces listing rules that signal a company's credibility, and helps determine how quickly and cheaply investors can buy or sell shares.

forward-looking statements regulatory

"This press release contains express or implied forward-looking statements pursuant to applicable securities laws."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

ADPKD medical

"XRx-008 program for ADPKD"

ADPKD stands for autosomal dominant polycystic kidney disease, a hereditary condition in which numerous fluid-filled sacs form and grow in the kidneys over time, gradually crowding out healthy tissue and often leading to reduced kidney function. For investors, ADPKD matters because it represents a clear medical need that drives demand for new drugs, diagnostic tests and medical procedures, shaping clinical trial activity, regulatory decisions and long-term healthcare costs—think of it as a plumbing system where many expanding balloons reduce water flow and require costly fixes.

Type 2 diabetic nephropathy medical

"XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-40858

XORTX Therapeutics Inc.

3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		XORTX Therapeutics Inc.
		(Registrant)
Date: April 1, 2026		By:	/s/ Allen Davidoff
		Name:	Allen Davidoff
		Title:	Chief Executive Officer

EXHIBIT INDEX

99.1 News release dated April 1, 2026

 

EXHIBIT 99.1

XORTX Confirms Effective Date of Share Consolidation

CALGARY, Alberta, April 01, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, further to its news release of March 26, 2026, the implementation of its share consolidation on the basis of one (1) new common share for every five (5) old common shares (the “Consolidation”) has received all required approvals of the TSX Venture Exchange and Nasdaq Stock Exchange and will occur on April 6, 2026.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at www.xortx.com.

 For more information, please contact:

Allen Davidoff, CEO		Nick Rigopulos, Director of Communications
adavidoff@xortx.com		nick@alpineequityadv.com
+1 403 455 7727		+1 617 901 0785

Forward Looking Statements

This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to, regulatory approvals, such as the TSXV; the ability to complete the Consolidation; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and, our ability to obtain and maintain intellectual property protection for our product candidates. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.

FAQ

What share consolidation did XORTX Therapeutics Inc. (XRTX) confirm?

XORTX confirmed a share consolidation where shareholders will receive one new common share for every five old common shares. The consolidation has all required approvals and is part of the company’s capital structure adjustments as it advances its clinical-stage pharmaceutical programs.

When will the XORTX (XRTX) share consolidation take effect?

The XORTX share consolidation will occur on April 6, 2026. On that date, the one-for-five consolidation will be implemented following approvals from the TSX Venture Exchange and Nasdaq Stock Exchange, aligning the company’s share structure with its ongoing clinical development strategy.

Which exchanges approved the XORTX (XRTX) share consolidation?

The share consolidation received required approvals from the TSX Venture Exchange and Nasdaq Stock Exchange. These approvals allow XORTX to implement its one-for-five consolidation on April 6, 2026, as part of managing its publicly traded common shares across multiple listings.

What therapeutic programs is XORTX Therapeutics Inc. (XRTX) developing?

XORTX is developing three clinically advanced products: XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease, and XRx-101 for acute kidney and organ injury linked to respiratory virus infections. It is also advancing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy.

What disease pathways does XORTX (XRTX) target with its drug candidates?

XORTX targets aberrant purine metabolism and xanthine oxidase to decrease or inhibit uric acid production. This biological focus underpins its programs for gout, progressive kidney diseases, and acute organ injury associated with respiratory virus infections, aiming to improve patient quality of life.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 5.5 KB